Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.7 million.

  • Aclaris Therapeutics' Other Accumulated Expenses rose 254.97% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 254.97%. This contributed to the annual value of $2.7 million for FY2024, which is 209.28% up from last year.
  • As of Q3 2025, Aclaris Therapeutics' Other Accumulated Expenses stood at $2.7 million, which was up 254.97% from $2.7 million recorded in Q2 2025.
  • Aclaris Therapeutics' Other Accumulated Expenses' 5-year high stood at $2.7 million during Q3 2025, with a 5-year trough of $217000.0 in Q4 2022.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $1.7 million (2022), whereas its average is $1.8 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Other Accumulated Expenses crashed by 8748.56% in 2022 and then soared by 111105.99% in 2023.
  • Aclaris Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.7 million in 2021, then plummeted by 87.49% to $217000.0 in 2022, then skyrocketed by 1111.06% to $2.6 million in 2023, then grew by 2.09% to $2.7 million in 2024, then rose by 1.94% to $2.7 million in 2025.
  • Its Other Accumulated Expenses was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.7 million in Q1 2025.